SEC 13F Intelligence

Rhenman & Partners Asset Management AB / BMRN

Rhenman & Partners Asset Management AB’s Biomarin Pharmaceutical Inc Position

Does Rhenman & Partners Asset Management AB own Biomarin Pharmaceutical Inc (BMRN)? Yes — 207.0K shares worth $12M (+1.44% of its 13F portfolio) as of Q1 2026, down from 215.0K shares the prior filed quarter.

Position Value
$12M
Q1 2026
Shares
207.0K
% of Portfolio
+1.44%
Quarters Held
30
currently held

Position History BMRN

Reported value by quarter
Q4 ’18: $15MQ4 ’18Q1 ’19: $21MQ2 ’19: $24MQ3 ’19: $20MQ4 ’19: $18MQ4 ’19Q1 ’20: $16MQ2 ’20: $23MQ3 ’20: $57MQ4 ’20: $45MQ4 ’20Q1 ’21: $14MQ2 ’21: $13MQ3 ’21: $19MQ4 ’21: $24MQ4 ’21Q1 ’22: $17MQ2 ’22: $12MQ3 ’22: $21MQ4 ’22: $26MQ4 ’22Q1 ’23: $21MQ2 ’23: $33MQ3 ’23: $34MQ4 ’23: $27MQ4 ’23Q1 ’24: $21MQ2 ’24: $21MQ3 ’24: $26MQ4 ’24: $16MQ4 ’24Q1 ’25: $19MQ2 ’25: $8MQ3 ’25: $10MQ4 ’25: $13MQ4 ’25Q1 ’26: $12Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026207.0K$12M+1.44%
Q4 2025215.0K$13M+1.19%
Q3 2025186.7K$10M+1.12%
Q2 2025149.7K$8M+1.04%
Q1 2025265.0K$19M+2.15%
Q4 2024250.6K$16M+1.69%
Q3 2024364.5K$26M+2.08%
Q2 2024251.5K$21M+1.99%
Q1 2024237.5K$21M+1.97%
Q4 2023282.5K$27M+2.72%
Q3 2023380.0K$34M+3.63%
Q2 2023380.0K$33M+3.47%
Q1 2023225.0K$21M+2.35%
Q4 2022254.0K$26M+2.74%
Q3 2022237.0K$21M+2.15%
Q2 2022140.0K$12M+1.32%
Q1 2022220.0K$17M+1.67%
Q4 2021265.0K$24M+1.57%
Q3 2021240.0K$19M+1.30%
Q2 2021160.0K$13M+0.91%
Q1 2021180.0K$14M+0.95%
Q4 2020510.0K$45M+3.65%
Q3 2020744.4K$57M+5.04%
Q2 2020190.0K$23M+2.53%
Q1 2020184.8K$16M+2.19%
Q4 2019210.0K$18M+1.95%
Q3 2019290.5K$20M+2.45%
Q2 2019281.3K$24M+2.65%
Q1 2019231.5K$21M+2.41%
Q4 2018176.5K$15M+1.72%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of BMRN.